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Background. The long-term success of organ transplantation
is influenced by numerous alloantigen-dependent and -indepen-
dent risk factors. However, only very little information is pres-
ently available on the influence of systemic immune-activating
processes following organ engraftment.
Methods. To simulate the clinical situation of sequential or-
gan transplantation, rat renal allograft recipients received addi-
tional immune activating stimuli (secondary donor-specific and
third-party skin grafts) after transplantation at serial time intervals
(4 and 8 weeks). The overall observation period was 16 weeks.
Results. All control animals survived the observation period.
In contrast, recipients receiving additional third-party or donor-
specific skin grafts were beginning to die 12 weeks after organ
engraftment with only few animals surviving 16 weeks. Sys-
temic immune activation by additional third-party and in par-
ticular by additional donor-specific skin grafts resulted in sig-
nificant temporary and long-term functional deterioration.
Morphologic changes progressed significantly, particularly after
a secondary challenge with donor-specific skin grafts. ED1
monocytes/macrophages, T-cell infiltrates, and intragraft mRNA
expression for CD25 were significantly elevated by 16 weeks,
following an additional immune challenge. Analysis of early
intragraft events showed strong up-regulation of CD25 tran-
scripts, suggesting fast stimulation of intragraft immune pro-
cesses.
Conclusion. Both alloantigen-specific and -unspecific sys-
temic immune activation processes, following experimental or-
gan transplantation, contribute to chronic graft deterioration.
Those results seem relevant for long-term immunosuppressive
protocols and clinical situations of sequential organ trans-
plantation.
Key words: chronic graft deterioration, immune activation, allorecogni-
tion, rat model, renal transplantation.
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Although short- and long-term graft function has im-
proved over the years, organ transplantation has not as
yet reached its goal as a successful lifelong replacement
therapy for irreversibly damaged organs [1]. Chronic
graft dysfunction represents the leading cause of long-
term graft failure [2]. The pathophysiology of this event
is currently conceptualized as being influenced by a vari-
ety of alloantigen-dependent and -independent factors
[3]. Numerous alloantigen-independent events such as
prolonged ischemia, donor age, brain death, previous
diseases of the donor, and length of intensive care treat-
ment may impact the quality of the graft. These events
may reduce the functional capacity and increase the im-
munogenicity of the graft prior to transplantation [4, 5].
Following engraftment, alloantigen-dependent events
such as acute rejection episodes are cited as the most
important risk factor for chronic graft deterioration. Al-
though grafts may demonstrate clinical stability, unrec-
ognized immunologic activating events may occur, con-
tributing to long-term destructive effects [6, 7].
As there is currently no established therapy available
for the improvement of long-term graft survival, thera-
peutic strategies have been focusing on decreasing the
impact of potential risk factors. However, risk factors
following organ engraftment such as specific or unspecific
immune activating events have not as yet been dissected
in detail.
Rates of end-stage renal failure following after heart
transplantation long-term ranging between 5% and 10%
have been reported [8, 9, 10]. Clinically, secondary organ
grafts in recipients already carrying a first graft are in-
creasingly performed. However, in a recent series of
renal allografts following previous heart, liver, or lung
grafts renal allograft survival was reduced compared to
the overall renal transplant population of this series [11].
Those events may also alter the immune response and
may consequently need a modified immunosuppression.
Furthermore, viral or bacterial infections are of particu-
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lar relevance as potential immune activating processes.
The contribution of cytomegalovirus (CMV) infections
on chronic graft rejection has been shown before in clini-
cal and experimental studies [12, 13]. In our current
study, we followed the impact of additional systemic
T-cell activating processes after organ engraftment on
chronic allograft nephropathy.
METHODS
Animals and operative procedures
Male inbred rats (Harlan-Winkelmann, Borchen, Ger-
many) were used throughout the experiments. Fischer
344 (RT11v1/F-344) renal allografts were transplanted
into LEWIS (LEW, RT11) recipients using standard mi-
crosurgical techniques [14]. Grafts were transplanted
orthotopically to recipient renal vessels and ureter by
end-to-end anastomosis using 10-0 Prolene. One native
kidney was removed during transplantation, the remaining
kidney 10 days later. Cyclosporine A (CyA) treatment
was given for 10 days at a dosage of 1.5 mg/kg/day to
overcome early acute rejection episodes in this model.
Grafts of this group (N  10) served as controls and
were followed for 16 weeks. Further groups received an
additional damaging manipulation 4 and 8 weeks after the
initial transplantation. Third-party [LEWIS  BROWN
NORWAY F1 (LEWxBN F1 9RT11  RT1n)] or donor-
specific (F-344, RT11v1) skin grafts were transplanted on
both flanks 4 and 8 weeks after the initial engraftment.
Long-term changes (16 weeks) were followed in all groups
(N  4/group/time interval). In additional groups, early
intragraft changes were tested 3 days following additional
skin grafts (skin graft 8 weeks after the initial organ trans-
plantation; N  5 per group).
Functional studies
Proteinuria has been shown previously as the most
sensitive marker for graft function in the rat renal allo-
graft model of chronic graft deterioration [15].
Following transplantation, urine samples (24-hour)
were collected serially at 2 weekly intervals. Protein ex-
cretion (mg/24 hours) was measured by precipitation
with 20% CCl3COOH. Turbidity was assessed at a wave-
length of 415 nm using a Hitachi 911 analyzer.
Histology
Kidneys were removed once animals were dying or 16
weeks after transplantation, respectively, and fixed in
5% buffered formalin. Paraffin sections were stained with
hematoxylin and eosin and periodic-acid Schiff (PAS) and
assessed by light microscopy. To determine the extent
of glomerulosclerosis and arteriosclerosis, glomeruli and
arteries/kidney were counted and the ratio expressed as
a percentage. The extent of cellular infiltrates, tubular
atrophy, and interstitial fibrosis was quantified on a 0 to
4 scale [4  strongest structural deterioration /20
fields of view/section were evaluated at 400].
Immunohistology
Portions of representative kidneys in experimental
and control grafts were collected when animals were
dying or at the end of the observation period, respec-
tively. Samples were snap-frozen in liquid nitrogen, cut
(4 m), fixed in acetone for 10 minutes, and air dried.
Following an preincubation with normal rabbit serum
(Dako Diagnostika GmbH, Hamburg, Germany) in or-
der to reduce unspecific background staining, samples
were incubated with primary mouse antibodies (mAbs)
to CD5 T cells (OX-19), CD4 T helper cells (W3/25),
CD8 cytotoxic T cells (OX-8), monocytes/macrophages
(ED-1), and major histocompatability complex (MHC)
class II (OX-3) (all mAbs from Serotec, Wiesbaden, Ger-
many). Sections were then stained with a secondary rab-
bit anti-mouse immunoglobulin G (IgG) followed by
the incubation with calf intestinal alkaline phosphatase/
mouse monoclonal anti-alkaline phosphatase complex
(APAAP) (Dako). Finally, complexes were visualized us-
ing the New Fuchsin substrate system (naphthol AS-BI
phosphate as a substrate and New Fuchsin as a simulta-
neous coupling agent) and counterstained with hematox-
ylin. Control staining was performed for all experiments
by isotype antibodies performed in parallel to the indi-
vidual experiments.
Positive cell counts were expressed as mean  SD of
cells/field of view; slides were blinded and 20 fields of
view/section were evaluated at 400 by two observers.
Reverse transcription-polymerase chain
reaction (RT-PCR)
Intragraft gene expression for relevant cells and cyto-
kines [CD3, CD25, tumor necrosis factor- (TNF-),
interferon- (IFN-), interleukin-4 (IL-4), Bclx and heme
oxygenase-1 (HO-1)] was assessed by real-time RT-PCR
at the end of the observation period by using Taqman
PCR machine. Early intragraft changes were tested in
additional groups 3 days following a secondary immune
activating event performed 8 weeks after the initial organ
engraftment.
Briefly, the amplification plot was examined early in
the reaction representing a log phase of product accumu-
lation. This was done by assigning an arbitrary threshold.
Once the threshold was chosen, the point at which the
amplification plot crossed the threshold was defined and
correlated to the constant expression of a housekeeping
gene defined as 	 CT [CT (gene of interest) – CT
(housekeeping gene)  2
 	CT].
Statistics
Kaplan-Meier test was used to determine statistical
significance of survival rates. Significance concerning
Heidenhain et al: Immune activation and chronic allograft nephropathy 1127
Table 1. Quantification of survival, function, and structural changes in allograft recipients with and without additional manipulations
Survival Morphologic Functional Cellular
16 weeks/time of death (%) changes deterioration infiltration
Controls 100   
Experimental groups
Additional systemic T cell activation
Third-party skin grafts
4 weeks following first treatment 75   
8 weeks following first treatment 50   
Donor-specific skin grafts
4 weeks following first treatment 25   
8 weeks following first treatment 25   
Changes in regard to morphology, renal function, and cellular infiltration are quantified on a 0 to 4 scale.
Fig. 1. Survival of renal allograft in recipients with and without further
manipulations. All animals without further manipulations survived the
observation period. In contrast, animals receiving additional skin grafts
4 and 8 weeks after organ engraftment started dying 12 weeks following
organ engraftment. *P  0.05; **P  0.01 vs. control.
functional deterioration, immunohistochemistry, RT-
PCR (metric scaled data), and morphologic changes (or-
dinal scaled data) were ascertained by analysis of vari-
ance (ANOVA), and Mann-Whitney test (two-sided).
RESULTS
At the end of the observation period (16 weeks), the
findings with regard to survival, structural changes, func-
tional deterioration, and cellular infiltration were sum-
marized quantitatively (Table 1). Control animals were
compared with experimental groups receiving an addi-
tional systemic immune activation.
Graft survival
All recipients without further manipulations survived
the observation period. In contrast, engraftment of addi-
tional donor-specific skin grafts 4 or 8 weeks after organ
engraftment reduced survival to 25% by the end of the
observation period (P  0.004 by 4 weeks; P  0.003 by
8 weeks vs. controls). When an additional third-party
skin graft was performed 4 weeks after the initial organ
transplantation, 75% of renal allograft recipients sur-
vived the observation period of 16 weeks (NS). Place-
ment of additional third-party skin grafts after 8 weeks
reduced survival to 50% (P  0.03) (Fig. 1).
LEWBNF1 were rejected after 8 3 days (average
SD), independent from the time interval between organ
transplantation and skin engraftment. Additional donor-
specific F-344 skin grafts grafted 4 and 8 weeks after the
initial organ engraftment were accepted long-term.
Graft function
Urinary protein excretion has been measured serially
in all groups. LEWIS control recipients of F-344 renal
allografts without further manipulations demonstrated
a moderate increase in proteinuria by week 16 (40  18
mg/24 hours).
Engraftment of additional third-party skin grafts 4 and
8 weeks following renal transplantation resulted in a
temporary increase in proteinuria (challenge by 4 weeks,
P  0.01; 8 weeks, P  0.003; measured 10 weeks after
organ transplantation). However, by the end of the ob-
servation period those differences had diminished. By
week 16, urinary protein excretion remained only statisti-
cally different in renal allograft recipients receiving an
additional third-party skin graft 8 weeks after the initial
organ transplantation, compared to nonmanipulated
controls (P  0.03). However, it has to be noted that
the long-term analysis (16 weeks) is restricted to the
survivors only.
Recipients of renal allografts receiving additional do-
nor-specific skin grafts 4 and 8 weeks after the initial
organ transplantation demonstrated significantly ele-
vated urinary protein excretion by week 14 (donor-spe-
cific skin graft by 4 weeks, P  0.00003; by 8 weeks, P 
0.01) (Fig. 2). As only 25% of rats receiving a secondary
donor-specific skin graft survived 16 weeks, statistic anal-
ysis by the end of the observation period was not per-
formed.
Morphology
Control animals without an additional immune chal-
lenge demonstrated strong cellular infiltrates by 4 weeks;
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Fig. 2. Allograft function following additional manipulations. Protein-
uria did not increase in control animals; however. engraftment of third-
party (A ) or additional donor-specific (B ) skin grafts resulted in a
significant long-term increase of urinary protein excretion. *P  0.05;
**P  0.01 vs. control; mean  SEM.
by week 8 glomerulosclerosis became evident (20%). By
week 16, only few cellular infiltrates were observed with
moderate signs of glomerulosclerosis and arteriosclerosis
(30% and 1 to 2, respectively); a few tubules were
atrophic while fibrosis was minor (1 to 2) (Fig. 3).
Systemic T-cell activation increased structural changes
significantly after both additional third-party and donor-
specific skin grafts. The engraftment of additional third-
party skin grafts 8 weeks after organ transplantation
increased arteriosclerosis by week 16 (P 0.01); tubular
atrophy (P  0.009) and interstitial fibrosis (P  0.02)
increased significantly compared to control grafts. In ad-
dition, cellular infiltrates had increased when additional
third party skin grafts were performed (P  0.02) (Fig.
3). Comparable results were obtained for additional skin
grafts 4 weeks after the initial organ transplantation,
albeit not showing significant differences for all morpho-
logic parameters examined (not shown).
Following donor-specific skin transplants, morpho-
logic alterations increased even more. When additional
skin transplants were performed after 8 weeks (P 
0.0008), glomerulosclerosis increased to almost 80% by
week 16. Similarly, arteriosclerosis (P  0.002), tubular
atrophy (P  0.009), or fibrosis (P  0.01) progressed.
Furthermore, strong cellular infiltrates were observed
following an additional donor-specific skin transplant
(P 0.007) (Fig. 3). Morphologic alterations by 16 weeks
were comparable when additional donor-specific skin
grafts were performed 4 weeks after the initial kidney
transplantation (not shown).
Immunohistology
Cells infiltrating unmodified control grafts by week 16
consisted of low numbers of ED-1 monocytes/macro-
phages, and moderate numbers of T cells (Fig. 4; Table
2). Both, endothelial cells and cellular infiltrates stained
for MHC class II (Table 2).
Increasing amounts of ED-1 monocytes/macro-
phages and CD4T cells were observed, following addi-
tional third-party and donor-specific skin grafts by week
4 and 8. At week 16, ED-1 monocytes/macrophages
(P  0.0004) and CD4/CD8 T cells were significantly
elevated (P  0.04), following additional donor-specific
skin grafts 8 weeks after the initial organ engraftment
(Fig. 4; Table 2).
Gene expression
By 16 weeks, CD25 was significantly elevated follow-
ing both, additional third-party and donor-specific skin
grafts (P 0.04 and P 0.05) (Fig. 5). mRNA expression
for IFN-, IL-4, Bclx, HO-1, and CD3 were not different
between groups receiving additional skin grafts and con-
trol animals by 16 weeks (not shown).
In additional groups, early gene expression profiles
were evaluated; 3 days following donor- or third-party
skin grafts performed 8 weeks after the initial kidney
transplantation, CD25 was strongly up-regulated follow-
ing a third-party skin graft (P  0.03) and even more
pronounced following the additional transplantation of
donor-specific skin (P  0.005) compared with the un-
challenged controls (Fig. 5).
DISCUSSION
Chronic graft deterioration remains the major threat
of long-term success after organ transplantation. While
organ-specific differences are observed, chronic graft re-
jection seems particularly detrimental in renal allografts.
Recent clinical studies have shown a half-life for renal
cadaver grafts ranging between 9 and 13 years, while
1-year graft and patient survival rates of 90% were re-
ported [1, 5, 16]. Unsatisfactory long-term graft function
is of particular clinical relevance, since no established clini-
cal treatment is currently available. A multitude of allo-
antigen-dependent and alloantigen-independent risk fac-
tors seem to be involved in the process and have been
extensively reviewed [3–5, 17, 18]. However, additional
immune activating processes following organ trans-
plantation and their impact on long-term graft function
have not as yet been studied extensively.
To analyze the contribution of secondary T-cell activa-
tion processes triggered outside the graft, we designed
the following series of experimental settings.
Secondary systemic T-cell activation was simulated in
two experimental series. Additional donor-specific skin
grafts represented systemic T-cell stimuli in a location
other than the graft, including a different lymphatic
drainage, with the graft as a mutual target. Using addi-
tional third-party skin grafts, we examined the effects
of a systemic T-cell activating process from a different
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Fig. 3. Structural changes. Histology of renal allografts by the end of the observation period (16 weeks) and those with additional manipulations
(8 weeks after the initial organ transplantation) (hematoxylin and eosin staining, 250). Structural changes advanced significantly by week
16 following additional third-party and even more pronounced following donor-specific skin grafts performed 8 weeks after the initial organ
transplantation.
location with an antigenic target disparate from the ini-
tially transplanted graft. All experimental series were
designed with similar intervals between the initial organ
transplantation and the secondary damaging event.
The F-344 to LEWIS donor/recipient combination
represents an established model for the development
of chronic graft deterioration. A low-dose, short-term
immunosuppressive treatment (CyA, 1.5 mg/kg/day 
10 days) is necessary in this model to overcome early
acute rejection episodes. Although no long-term immu-
nosuppression is applied, progressive functional and
structural changes in this experimental model are compa-
rable to the clinical situation of chronic allograft ne-
phropathy. Strong humoral and cellular responses are
present in this model at 2 weeks following transplanta-
tion. Immune activation diminishes by weeks 4 and 8;
infiltrating T cells are reduced, while increasing numbers
of monocytes/macrophages are observed; during this
time chronic graft rejection can be reversed by retrans-
plantation into the syngeneic donor, suggesting the de-
pendency on specific immune processes within this time
period [19, 20]. In our experimental design, secondary
specific and unspecific systemic T-cell activating events
were performed after 4 and 8 weeks following the initial
organ engraftment to test their effects at different levels
of immune activation in this model. An earlier time point
(2 weeks) was omitted from the experimental design,
as effects from residual CyA could not be completely
excluded in our model. Indeed, in a separate set of exper-
iments (not shown) we were able to show that IL-2 pro-
duction, following a 10-day treatment course with CyA,
was still significantly reduced at 2 weeks, although CyA
could not be detected in the serum.
Additional third-party skin grafts performed 4 and 8
weeks after the initial organ transplantation, influenced
graft survival, function, and structural changes signifi-
cantly. Most important, the majority of grafts discon-
tinued to function after additional third-party skin grafts
performed by week 8 and additional donor-specific skin
grafts performed between 4 and 8 weeks following the
initial organ transplantation. Already 3 days after this
extrarenal challenge, we observed a strong up-regulation
Heidenhain et al: Immune activation and chronic allograft nephropathy1130
Fig. 4. Cellular infiltrates. ED-1 monocytes/macrophages (A ) and CD4 T cells (B ) stained 16 weeks after transplantation (magnification
400). A significant increase of ED-1 monocytes/ macrophages and CD4 T cells was observed following both additional third-party and donor-
specific skin grafts after an 8-week interval.
of CD25 transcripts in renal allografts receiving third-
party skin grafts and particularly following donor-specific
skin grafts, suggesting a fast stimulation of T-cell processes.
The enhanced intragraft immune activation was still de-
tectable by week 16, as shown by elevated cellular in-
filtrates with ED-1 monocytes/macrophages and CD4
T cells and enhanced CD25 mRNA expression.
CD25 is expressed on both recently activated effector
T cells and regulatory T cells. Thus, we cannot rule out
the accumulation of regulatory T cells by this analysis.
However, the association with accelerated graft injury
suggest accumulation of effector processes.
Clinically, sequential organ transplantations, such as
kidney after heart, liver, or pancreas transplantations
are performed with increasing numbers. Chronic graft
deterioration was accelerated in our model by secondary
systemic immune-activating processes to donor-related
antigens, when graft recipients were rechallenged with
donor-specific skin grafts. This experimental model re-
sembles the clinical relevant situation of placing second-
ary grafts from donors with human leukocyte antigen
(HLA) mismatches related to the mismatches of the first
graft. Our experimental data suggest that repeated organ
transplantations with the same (or partially identical) mis-
match represent not only a risk for the secondary graft it-
self, but also for a well-functioning primary organ graft
when similar mismatches are observed. The strong immu-
nogenicity of skin grafts based on a high frequency of
mature antigen-presenting cells (APCs), and prolonged
persistence of the alloantigen may be of particular rele-
vance in this context. Furthermore, the expression of the
CD103 ligand (E-cadherin) on skin and kidney epithelial
cells resulting in specific activation of CD103 (E7
integrin) T cells may be associated with an accelerated
rejection in kidneys following skin grafts [21]. Previous
own experiments (not shown) demonstrated that single
blood transfusions were unable to initiate an acceleration
of the rejection process. However, repeated blood trans-
fusion, might be more immunogeneic.
The F-344→LEWIS model based on a single MHC
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Fig. 4. (Continued.)
Table 2. Cellular infiltrates and MHC II expression in all groups were examined and quantified by the end of the observation period (16 weeks)
ED-1 CD4 CD5 CD8 MHC
Cells/field of view by 16 weeks/time of death monocytes/macrophages T cells B/T cells T cells class II
Control 224 769 4310 342 992
Experimental groups
Additional systemic T cell activation
Third-party skin grafts
4 weeks following first treatment 323 924 4717 329 1085
8 weeks following first treatment 415a 9211 454 4912 1063
Donor-specific skin grafts
4 weeks following first treatment 332a 1039 413 341 1054
8 weeks following first treatment 553b 1015a 462 5918a 1084
MHC is major histocompatability complex.
Mean  SD; aP  0.05; bP  0.001 vs. control.
class I mismatch demonstrates that even long-lasting
grafts are very sensitive to a rechallenge with a single-
donor MHC antigen. These data suggest a careful adapta-
tion of immunosuppression in clinically relevant situations.
Mechanisms of our experimental findings may include the
activation and intragraft accumulation of alloreactive T
cells (via both direct and indirect allopresentation) and
B cells associated with secondary transplants. We have
recently shown, that alloreactive effector T cells accumu-
late in kidney grafts, even if they are generated in other
animals or in vitro [22]. In fact, in our experiments,
primary kidney grafts demonstrated stronger cellular in-
filtrates following a challenge with additional donor-spe-
cific skin grafts.
Heidenhain et al: Immune activation and chronic allograft nephropathy1132
Fig. 5. Gene expression. CD25 mRNA was strongly up-regulated early
(3 days) and at the end of the observation period following third-
party or donor-skin grafts performed 8 weeks after the initial kidney
transplantation. *P  0.05; **P  0.01 vs. control; mean  SEM. RT-
PCR is reverse transcription-polymerase chain reaction.
Acceleration of chronic graft deterioration by second-
ary immune-activating processes to unrelated antigens
in our model resembles the clinical relevant situation of
secondary organ grafts not related to the original donor/
recipient mismatches. Although the detrimental effects
on long-term graft function are less pronounced than in
the donor-specific situation, we observed a highly signifi-
cant acceleration of chronic graft injury following grafting
of third-party skins. Thus, secondary transplantations of
long-term graft recipients might result in damaging the
primary graft, even if no linked mismatches are detect-
able. Intragraft analyses showed enhanced intragraft im-
mune cell accumulation and activation. One may also
envision similar events following systemic viral or bacte-
rial infections. In fact, several reports have been showing
an association between viral infections and acute and
chronic graft rejection, without detecting the virus in the
graft [23]. Indeed, increased frequencies of CMV specific
T cells compared to donor-specific T cells have been shown
in graft rejecting recipients [23]. What are the mechanisms
of graft injury associated with non-donor antigen-related
T cells? Activated memory/effector T cells show an altered
homing to tissues with a preference of homing to in-
flamed endothelium or tissues. Although not tested in
our system, this process is associated with the up-regula-
tion of several adhesion molecules and chemokine recep-
tors in areas of inflammation. Activated endothelial cells
in organ grafts may support a preferential homing of
activated T cells independent from the presence of the
target antigen. In fact, labeled alloreactive memory/
effector T cells infused into rats receiving kidney trans-
plants, accumulate preferably in donor-specific grafts.
In addition, third-party or even syngeneic grafts attract
more alloreactive T cells than normal kidneys [22]. These
data suggest that “inflamed” kidneys attract activated T
cells, independent from their specificity.
Summarizing our findings, we did observe that second-
ary systemic immune activating events, such as third
party and particularly donor-specific skin grafts, acceler-
ated chronic graft deterioration. Activation of alloanti-
gen-specific memory and effector T cells may play a role
in this context. Avoiding those situations seems impor-
tant to improve long-term graft function in clinical situa-
tions. Those experimental data seem relevant for clinical
protocols aiming to reduce immunosuppression long-
term and in clinical situations of sequential organ trans-
plantation.
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